Johnson & Johnson (J&J) posted H1 2025 revenue of USD 45.6 billion, up 4.1% year-on-year, driven by oncology growth. Darzalex (daratumumab) led sales with USD 6.8 billion (+21.7%), while BCMA CAR-T therapy Carvykti (ciltacabtagene autoleucel) surged to USD 808 million, on track for USD 2 billion annually. The myeloma portfolio expanded with CD3/BCMA bispecific Tecvayli (teclistamab) at USD 317 million (+18.2%) and GPRC5D-targeted Talvey (talquetamab) at USD 192 million (+52%).

However, immunology sales fell 14.1% to USD 7.7 billion due to Stelara (ustekinumab) biosimilar competition (-38.6%). J&J offset declines with Tremfya (guselkumab, +25%) and new acquisitions like FcRn inhibitor nipocalimab. Neuroscience grew 48% with Spravato (esketamine), and the USD 14.6 billion Intra-Cellular deal added schizophrenia drug Caplyta (lumateperone). The company raised its 2025 revenue forecast to USD 92.7-93.1 billion.

According to PharmCube's NextBiopharm® database, Darzalex annual sales (image below) have been slowing down over the last four years. Click here to request a free trial for NextBiopharm®.